Characteristics at baseline | Center 1 Set (N = 303) | Center 2 Set (N = 227) | P Chi2 | ||
---|---|---|---|---|---|
N (%) | Median (Min-Max) | N (%) | Median (Min-Max) | ||
Sex | 0.64 | ||||
Male | 181 (60) | 131 (58) | |||
Female | 122 (40) | 96 (42) | |||
Age | 62 (IQR, 19) | 60 (IQR, 23) | 0.07 | ||
< 50 | 55 (18) | 42 (19) | |||
50–65 | 116 (38) | 107 (47) | |||
≥ 65 | 132 (44) | 78 (34) | |||
Performance status | 0.82 | ||||
ECOG 0–1 | 278 (92) | 207 (91) | |||
ECOG 2 | 25 (8) | 20 (9) | |||
BMI (kg/m2) | 25 (16–39) | 26 (16–45) | -a | ||
< 18.5 | 13 (4) | 9 (4) | |||
18.5–25 | 147 (49) | 83 (37) | |||
≥ 25 | 143 (47) | 107 (47) | |||
NA | 0 | 28 (12) | |||
Previous treatments | 1 (0–4) | 1 (0–6) | <0.001 | ||
0 | 9 (3) | 106 (47) | |||
1 | 185 (61) | 67 (30) | |||
2 | 74 (24) | 32 (14) | |||
3 | 27 (9) | 19 (8) | |||
4 and more | 8 (3) | 3 (1) | |||
Cancer localization | 0.01 | ||||
Sarcomas | 123 (40) | 91 (40) | |||
Urological | 78 (26) | 35 (15) | |||
Gastrointestinal | 54 (18) | 63 (28) | |||
Breast | 29 (10) | 20 (9) | |||
Other | 19 (6) | 18 (8) | |||
Involved areas | 0.55 | ||||
Loco-regional disease | 18 (6) | 19 (8) | |||
1–2 metastatic sites | 223 (74) | 164 (72) | |||
≥ 3 metastatic sites | 62 (20) | 44 (19) | |||
Hemoglobin level | 0.08 | ||||
< Normal | 106 (35) | 94 (41) | |||
Normal | 196 (65) | 126 (56) | |||
NA | 1 (0.3) | 7 (3) | |||
Leukocyte level | 0.18 | ||||
< Normal | 14 (5) | 15 (6) | |||
Normal | 255 (84) | 171 (75) | |||
> Normal | 33 (11) | 33 (15) | |||
NA | 1 (0.3) | 8 (4) | |||
Albumin level | -a | ||||
< Normal | 25 (8) | 87 (38) | |||
Normal | 236 (78) | 111 (50) | |||
NA | 32 (11) | 28 (12) | |||
LDH level | -a | ||||
< Normal | 133 (44) | 137 (60) | |||
Normal | 55 (18) | 51 (23) | |||
NA | 111 (37) | 34 (15) |